Supplementary Tables – Impact of fast-track regulatory designations on strategic commercialisation decisions for autologous cell therapies
dataset
posted on 25.01.2022, 08:51 by Figshare Future Science GroupFigshare Future Science Group, Ching Lam, Edward Meinert, Aidong Yang, Zhanfeng Cui|
Supplementary Material 1. Early-access designations in the US, EU, Japan and China Supplementary Material 3. Distance between cities in miles Supplementary Material 5. Case study parameters Supplementary Material 6. Facility parameters Supplementary Material 7. Equipment |
Funding
CRMI Technology Centre at the University of Oxford
History
References
- https://doi.org/10.4269/ajtmh.16-0600
- https://www.fda.gov/files/drugs/published/Overview-of-FDA-Expedited-Programs-with-a-Focus-on-the-Breakthrough-Therapy.pdf
- 10.1016/j.biologicals.2015.04.004
- 10.1002/term.2428
- https://www.mhlw.go.jp/english/policy/health-medical/pharmaceuticals/140729-01.html
- https://www.pmda.go.jp/files/000219466.pdf
- http://www.webcitation.org/73nSO5868
CC BY-NC-ND 4.0